Comparative Pharmacology
Head-to-head clinical analysis: LEVETIRACETAM IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVETIRACETAM IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
LEVETIRACETAM IN SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
6-8 hours in adults; prolonged in elderly (10-11 h) and renal impairment (up to 25 h in ESRD)
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
66% renal (unchanged), 27% as inactive metabolite (UCB L057) via renal; <1% fecal
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte